Recruiting

Continuous Infusions vs. Scheduled Bolus Infusions

Sponsor:

Stanford University

Code:

NCT03230565

Conditions

Surgical Procedure, Unspecified

Pain, Postoperative

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ropivacaine

Ropivacaine

Study Details

Brief summary:

The goal of the study is to compare continuous infusions and scheduled bolus infusions for peripheral nerve blocks and their effect on post-surgical pain.

Conditions

Surgical Procedure, Unspecified

Pain, Postoperative

Study ID

NCT03230565

Start date

Jun 1, 2018

Status verified date

Nov, 2025

Completion date

Dec, 2026

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adult patients presenting for nerve block catheters for post-operative analgesia
  • ASA physical status I, II, or III.

Exclusion Criteria:

  • Pregnancy
  • Incarceration
  • Age <18
  • BMI >35
  • Pre-operative opioid use >30 mg morphine equivalents per day
  • Inability to communicate with investigators by telephone
  • Pre-existing neuropathy of the operative extremity.

Study Design

Enrollment

240 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Continuous Infusion

Local anesthetic medication (Ropivacaine 0.2%) is provided at a continuous basal rate.

active comparator: Intermittent Bolus Infusion

Local anesthetic medication (Ropivacaine 0.2%) is provided in scheduled, intermittent boluses.

Interventions

Ropivacaine

Patient will be given a continuous infusion of local anesthetic.

Ropivacaine

Patient will be given a scheduled intermittent bolus of local anesthetic.

Primary outcome measure

  • Post-surgical pain [ Time Frame: Post-operative day 0, 1, and 2 ]

Central Contacts and Locations

Central contacts

Aaron J Deng, BS

408-914-5494adeng1@stanford.edu

Locations

Stanford University

Recruiting

Stanford, California, United States, 94305

Principal Investigator:

Jean Louis-Horn, MD

More Information

Sponsor

Stanford University

Last update posted

Dec 8, 2025

Last verified

Nov, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Stanford University on 2025-12-08.